This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

TRADE NEWS: Agilent Technologies Introduces New Exome Optimized For Clinical Research Sequencing

Stocks in this article: A

Agilent Technologies Inc. (NYSE:A) today introduced the SureSelect Clinical Research Exome. The performance-optimized exome design was developed in collaboration with researchers from Emory University and the Children’s Hospital of Philadelphia.

SureSelect Human All Exon V5 was used as the core for the new design. Performance has been enhanced in disease-associated regions, providing 10 percent deeper coverage within these targets from only 4Gb of sequencing, while maintaining excellent coverage in other exome regions.

“Our goal was to create a comprehensive exome design that provides higher coverage in regions that are associated with human disease,” said Maduri Hedge, professor of Human Genetics at Emory University. “Agilent’s ability to enhance current targets and add custom content to the Human All Exon V5 provided an ideal solution to help us achieve this.”

The disease-relevant regions in the clinical research exome consist of gene targets commonly associated with, or known to cause, disease, including targets identified in OMIM, HGMD and NCBI’s ClinVar databases. Additional ancestry- and identity-informative content has also been included to facilitate sample tracking. Custom content can be added to the Clinical Research Exome using SureDesign, a free online design tool for SureSelect. The Clinical Research Exome targets approximately 54Mb of content and is optimized for coverage uniformity, enabling proportional performance improvement as sequencing allocation per library is increased. The SureSelect Clinical Research Exome can be paired with existing SureSelect kits to provide significantly reduced hybridization times—as little as 90 minutes—and provide sequencing-ready libraries in just one day.

“We are pleased to share this exceptional sequencing tool with the research community,” said Victor Fung, senior director of Marketing for Agilent’s Diagnostics and Genomics Solutions business. “It is unmatched in its ability to provide superior coverage, uniformity and efficiency in key regions, enabling up to two-and-a-half times greater sample throughput than any other exome available today.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs